French decree confirms separate payment for ICDs and vascular implants:
This article was originally published in Clinica
Executive Summary
The French health ministry has published a decree confirming that implantable defibrillators and vascular implants are to be paid for separately from the standard stay group (GHS) tariffs. This is the French equivalent of the diagnosis-related group scheme of charging for hospital treatment. The decree, dated July 29, was published in the Journal officiel on September 2 and contains a list of the codes that specify the precise implants covered by the ruling.
You may also be interested in...
Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: